Pharma & Biotech Mergers & Acquisitions News
Biotechnology
California-based clinical-stage biotech Tempest Therapeutics has announced that the company plans to explore a full range of strategic alternatives to advance its promising clinical stage programs and maximize stockholder value. 10 April 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
South Africa's largest health care company Adcock Ingram (AIP: SJ) says it has reached an agreement to purchase certain assets of Indian pharmaceutical firm Cosme Farma Laboratories, for 708 million rupees ($11.9 million) in cash. The acquisition, through its Indian subsidiary Adcock Ingram Healthcare, will expand the company's access to the high-growth $16 billion Indian pharmaceutical market. 10 July 2012
Pharmaceutical
Australia-based Alchemia (ASX: ACL) says it is progressing well with preparations to demerge its oncology assets, with a proposal anticipated to be put to shareholder vote in late September/early October 2012. 9 July 2012
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) says that it has completed the previously indicated sale of the assets of its subsidiary, Aptium Oncology. The company first revealed that it planned to divest these assets, as well as its dental and medical devices unit Astra Tech last year. 9 July 2012
Pharmaceutical
German drug major Merck KGaA )MRK: DE) revealed this morning that its Phase III EXPAND trial, which assessed Erbitux (cetuximab) in combination with cisplatin and capecitabine as a first-line treatment for patients with advanced gastric adenocarcinoma (AGA) including adenocarcinoma of the gastro-esophageal junction (GEJ), did not meet its primary endpoint of extending the length of time that patients live without their disease getting worse (progression-free survival - PFS), as determined by independent review. 5 July 2012
Pharmaceutical
Australia's Blackmores (ASX:BKL) says that it has agreed to acquire 100% of the issued share capital of FIT-BioCeuticals, an established Australian leader in the practitioner-only supplements market, for a cash payment up to a maximum of A$40 million ($41 million) and will be fully debt-funded from additional banking facilities. 3 July 2012
Pharmaceutical
US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag GmbH yesterday announced it has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment. 29 June 2012
Pharmaceutical
US drugstore chain Walgreen (NYSE: WAG) has agreed to acquire a 45% holding in pharmacy, health and beauty retailer Alliance Boots for $6.7 billion, and has an option - but not an obligation - to purchase the rest of the company in about three years time. 20 June 2012
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) said Friday that it has agreed to acquire OraPharma, a USA-based specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. 18 June 2012
Pharmaceutical
This morning saw a flurry of acquisition announcements by pharma companies. First up, Italy's Newron Pharmaceuticals (SIX: NWRN) revealed that it has signed an agreement with the key shareholders of Stockholm-based privately-owned NeuroNova for the acquisition of up to 100% of its shares, in an all-share transaction valuing NeuroNova at 15.4 million euros ($19.2 million) at closing share price June 11, 2012). 13 June 2012
Pharmaceutical
The US Federal Trade Commission will require health care giant Johnson & Johnson (NYSE: JNJ) to sell its system for surgically treating serious wrist fractures, resolving charges that J&J's proposed $21.3 billion acquisition of Switzerland-headquartered Synthes (The Pharma Letter April 27, 2011) would illegally reduce competition for these systems. 12 June 2012
Pharmaceutical
Global drugs behemoth Pfizer (NYSE: PFE) yesterday announced the next steps in the strategic alternatives review process for the company's animal health business, as part of its plans to divest non-core operations such as infant nutrition (sold to Nestle for $11.85 billion; The Pharma Letter April 24) and Capsugel (acquired by Kohlberg Kravis Roberts last year for $2.38 billion: TPL April 5, 2011). 8 June 2012
Pharmaceutical
Miami, USA-based OPKO Health (NYSE: OPK) has entered into a definitive agreement to acquire a 45% stake in an unnamed private Israeli company that produces a third-generation hepatitis B vaccine - Sci-B-Vac - in its state of the art biologics manufacturing facility in Rehovot. Financial terms of the transaction were not disclosed. 6 June 2012
Pharmaceutical
Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) said yesterday that it has now completed its previously-announced acquisition of privately-held US company URL Pharma, for an upfront payment of $800 million (The Pharma Letter April 12). 6 June 2012
Pharmaceutical
UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile takeover offer for Human Genome Sciences (NSQ: HGSI) unless the U.S. biotechnology company dropped a shareholder rights plan or "poison pill" imposed to block the deal, Reuters and other news sources have reported. 24 May 2012
Pharmaceutical
USA-based Agilent Technologies (NYSE: A) and EQT, a Swedish private equity group, have entered into an accord to acquire Denmark-based cancer diagnostic company Dako. The $2.2 billion all cash acquisition (on a debt-free basis) is the largest in Agilent's history. 21 May 2012
Pharmaceutical
In a second acquisition move within a matter of months, USA-based specialty drugmaker Cornerstone Therapeutics has made a takeover bid for EKR Therapeutics, a privately-held specialty pharmaceutical company focused on the acute-care hospital setting. 16 May 2012
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has agreed to acquire certain assets from University Medical Pharmaceuticals Corp, a specialty pharmaceutical company focused on skincare products, for approximately $64 million plus potential milestones based upon attainment of future revenue targets. University Medical's main brand is AcneFree, a leading retail over-the-counter (OTC) acne treatment. 4 May 2012
Pharmaceutical
USA-based Hologic (Nasdaq: HOLX) said it has reached an agreement to acquire Gen-Probe (Nasdaq: ASDAQ) for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion. The all-cash transaction, approved by both companies' boards of directors, is expected to be funded through available cash and additional financing of term loans and high yield securities. The transaction is expected to be completed in the second half of calendar 2012. 3 May 2012
Pharmaceutical
USA-based Pall Corp (NYSE: PLL) has entered into an agreement to sell certain assets of its blood collection, filtration and processing product lines, as well as equipment for transfusion medicine, to Haemonetics Corp (NYSE: HAE) for around $550 million. 30 April 2012
Pharmaceutical
US drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) said last week that it has signed a definitive accord to acquire privately-held, UK-headquartered EUSA Pharma for $650 million in cash and a potential $50 million milestone. 29 April 2012
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Pharmaceutical
US private equity firm Vance Street Capital has expanded its life sciences manufacturing platform with the acquisition of Irish contract manufacturer Zenith Adhesive Components, adding further technical capabilities and boosting regional reach. 4 April 2025
Pharmaceutical
Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt Pharmaceuticals and Endo, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 2 April 2025
Pharmaceutical
Japanese drugmaker Sumitomo Pharma said yesterday that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen ($480 million) in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. 2 April 2025
Pharmaceutical
Florida-based MIRA Pharmaceuticals, a pharma company developing therapeutics for neurologic and neuropsychiatric disorders, has signed a binding letter of intent (LOI) to acquire privately held Delaware firm SKNY Pharmaceuticals. 24 March 2025
Pharmaceutical
Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance (fluticasone propionate). 20 March 2025
Pharmaceutical
Chinese pharmaceutical company Fosun Pharmaceutical Group has agreed to sell its stake in private hospital operator United Family Healthcare to an investment firm owned by US private equity giant Warburg Pincus. 14 March 2025
Pharmaceutical
USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the privately-held Swiss drugmaker is now a wholly-owned subsidiary of Azurity. 14 March 2025
Pharmaceutical
Ireland-based Mallinckrodt Pharmaceuticals and Endo Inc have agreed to combine in a stock and cash deal worth $6.7 billion, after the pair emerged from bankruptcy processes linked to liabilities over the US opioid crisis. 13 March 2025
Pharmaceutical
Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based pharmaceutical company at approximately £362 million ($468 million). 11 March 2025
Pharmaceutical
USA-based Endo Inc today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics. 11 March 2025
Pharmaceutical
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and AstraZeneca. US pharma major AbbVie became the latest entrant to the weight management sector, striking a deal with Gubra for its obesity candidate GUB14295. On the M&A front, Ireland-headquartered Jazz Pharmaceuticals announced it is acquiring Chimerix for around $935 million to expand its oncology portfolio. USA-based scPharmaceuticals gained US Food and Administration (FDA) approval for its supplemental new drug application (sNDA) for Furoscix in chronic kidney disease (CKD). 9 March 2025
Pharmaceutical
Private equity firms acquiring assets were among the most eye-catching deals in pharma M&A during February. 6 March 2025
Pharmaceutical
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire US biopharma company Chimerix for $8.55 per share in cash, representing a total consideration of around $935 million. The news sent Chimerix’ shares rocketing almost 70% to $8.40. 5 March 2025
Pharmaceutical
French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics. 26 February 2025
Pharmaceutical
Kelso Pharma, the British specialty pharma business backed by Apposite Capital, today announced the acquisition of the UK pharma business, Alturix Holdings Limited. Financial terms were not disclosed. 24 February 2025
Pharmaceutical
US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Australia-based Mayne Pharma with the aim of expanding its health portfolio. 21 February 2025
Pharmaceutical
FibroGen today announced the sale of its China subsidiary to UK pharma major AstraZeneca for around $160 million, with the news sending the California-based company’s shares soaring 27% to $0.71. 20 February 2025
Pharmaceutical
An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International. 12 February 2025
Pharmaceutical
Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, along with the intellectual property rights to Esbriet (pirfenidone) in the USA, from Genentech, a subsidiary of Swiss pharma giant Roche. 11 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze